China Universal Asset Management Company’s SpringWorks Therapeutics SWTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-15,031
Closed -$663K 496
2025
Q1
$663K Sell
15,031
-742
-5% -$34.2K 0.06% 217
2024
Q4
$570K Buy
15,773
+1,488
+10% +$52K 0.05% 238
2024
Q3
$458K Buy
14,285
+5,582
+64% +$209K 0.05% 232
2024
Q2
$328K Sell
8,703
-5,491
-39% -$231K 0.05% 180
2024
Q1
$699K Buy
14,194
+6,957
+96% +$322K 0.09% 153
2023
Q4
$264K Buy
7,237
+5,625
+349% +$147K 0.05% 184
2023
Q3
$37.3K Buy
1,612
+792
+97% +$21.7K 0.01% 249
2023
Q2
$21.5K Sell
820
-27
-3% -$710 0.01% 260
2023
Q1
$21.8K Buy
847
+213
+34% +$6.22K 0.01% 208
2022
Q4
$16.5K Buy
634
+171
+37% +$4.21K 0.01% 187
2022
Q3
$13K Buy
+463
New +$13.3K 0.01% 185

Other funds holding SWTX

China Universal Asset Management Company's SWTX Position: Q2 2025 in Review

China Universal Asset Management Company sold out of SpringWorks Therapeutics (SWTX) in Q2 2025, closing a stake of 15,031 shares — an estimated $663K sold.

China Universal Asset Management Company first reported a position in SWTX in Q3 2022 and held it in 11 quarters. The position peaked at $699K in Q1 2024. 222 funds tracked by Wall St. Rank hold SWTX as of Q2 2025.

  • China Universal Asset Management Company reported no remaining SpringWorks Therapeutics position as of Q2 2025 after selling out during the quarter.
  • China Universal Asset Management Company sold 15,031 SpringWorks Therapeutics shares in Q2 2025, an estimated $663K.
  • China Universal Asset Management Company first reported a position in SpringWorks Therapeutics in Q3 2022 and held it in 11 quarters.
  • China Universal Asset Management Company's SpringWorks Therapeutics position peaked at $699K in Q1 2024.
  • 222 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q2 2025.

Based on China Universal Asset Management Company's 13F filing for Q2 2025, filed 28 Aug 2025.